GlassScriptPhysician profile
John D Caffaratti
NPI 1265418255
$1,040.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $890 · 2020: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $200.16 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $156.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $121.27 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.19 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.40 | 2019-2020 | |
| Amarin Pharma, INC. | $55.48 | 2019 | |
| Pfizer INC. | $53.97 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $51.77 | 2019-2020 | |
| Vifor Pharma, INC. | $39.97 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.01 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Caffaratti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.